A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

AG Ken Paxton pushed debunked misinformation about COVID-19 vaccines. What a shame the damage can’t be undone as easily as ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

At the urging of the group Do No Harm, a 2-1 court panel revisted a decision it issued last year holding the organization ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will be paying its dividend of $0.43 on the 7th of ...

Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...

From condemning the Jan. 6 Capitol riots to helping fund the President-elect’s impending inauguration, recent years have seen ...

Texas Attorney General Ken Paxton filed a notice of appeal on Wednesday to continue his lawsuit against Pfizer Inc., for its ...

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...